<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03267368</url>
  </required_header>
  <id_info>
    <org_study_id>2017-151</org_study_id>
    <nct_id>NCT03267368</nct_id>
  </id_info>
  <brief_title>Comprehensive Care Program SBRT</brief_title>
  <official_title>Pilot Trial of Clinical Implementation of a Comprehensive Care Program for Early Stage Medically Inoperable/Borderline Operable Lung Cancer Patients Undergoing Stereotactic Radiotherapy (SBRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary (lung) rehabilitation, which is done under the guidance of lung&#xD;
      specialists/therapists. It includes breathing exercises, physical exercises, and exercises to&#xD;
      increase tolerance of activity (stamina). This type of lung rehab has been shown to improve&#xD;
      symptoms, quality of life, breathing, and walking distance. It has also been shown to&#xD;
      decrease hospitalization and death rates in chronic obstructive pulmonary disease (COPD) and&#xD;
      lung cancer patients.&#xD;
&#xD;
      Comprehensive Care Management Program (CCMP), a program that includes educational sessions&#xD;
      for tobacco cessation, phone calls, and a home action plan has also demonstrated benefit in&#xD;
      addition to the pulmonary rehabilitation.&#xD;
&#xD;
      In this study, the investigators have an opportunity to identify and intervene with COPD&#xD;
      patients. The vast majority of early stage lung cancer patients are much more scared of their&#xD;
      cancer than their COPD. Upon identification of COPD and recognition of patient tobacco habits&#xD;
      for patients planned to undergo SBRT, interventions can potentially be made that will reduce&#xD;
      COPD hospitalization rates, second primary lung cancer rates, and likely death rates. The&#xD;
      interventions are broadly available and relatively easily instituted and include the&#xD;
      following: seeing a doctor to diagnose their other underlying illness or illnesses (both&#xD;
      respiratory and cardiovascular), smoking cessation if they are smokers, and CCMP's and&#xD;
      pulmonary rehabilitation which have shown measurable COPD benefits in prior trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: To evaluate the technical feasibility and delivery of a comprehensive&#xD;
      program that leads to prevention and management of symptoms of COPD in early stage lung&#xD;
      cancer patients undergoing curative therapy, promotes and leads to smoking cessation, and&#xD;
      evaluates potentially unknown cardiopulmonary co-morbid or therapeutically-induced diseases&#xD;
      in the cancer patient.&#xD;
&#xD;
      Secondary objective(s):&#xD;
&#xD;
        1. To document overall survival of patients undergoing lung SBRT plus preventative care,&#xD;
           including evaluation and treatment by a pulmonologist and cardiologist in combination&#xD;
           with a tobacco cessation program (for those currently smoking or within 6 months of&#xD;
           quitting), and pulmonary rehabilitation. Overall survival and other tumor recurrence and&#xD;
           survival endpoints will be compared to historical controls.&#xD;
&#xD;
        2. To evaluate quality of life (QOL) changes of patients undergoing lung SBRT with usual&#xD;
           care plus evaluation and treatment by a pulmonologist and cardiologist in combination&#xD;
           with a tobacco cessation program (for those currently smoking), and pulmonary&#xD;
           rehabilitation.&#xD;
&#xD;
        3. To evaluate primary tumor control, regional control, distant metastasis and&#xD;
           progression-free and cause-specific survival rates.&#xD;
&#xD;
        4. To evaluate toxicity rates, including pulmonary and cardiotoxicity after SBRT. Diagnosis&#xD;
           and management of cardiopulmonary toxicities may be greater for these patients&#xD;
           undergoing routine evaluation by specialist physicians.&#xD;
&#xD;
        5. To evaluate smoking cessation rates after employing an Ask, Assist and Refer method for&#xD;
           smoking cessation.&#xD;
&#xD;
        6. To evaluate second primary lung cancer rates and compare them to historical controls.&#xD;
&#xD;
        7. To evaluate changes in pulmonary function, 6-minute walk test and V02 max values with&#xD;
           participation in pulmonary rehabilitation.&#xD;
&#xD;
        8. To document hospitalization rates after SBRT using these preventative care strategies.&#xD;
&#xD;
        9. To explore the impact of SBRT on ventilation and changes in functional lung using&#xD;
           4-Dimensional computed tomography(4DCT) before and after SBRT.&#xD;
&#xD;
       10. To study the potential impact of SBRT on cardiac function using pre-and post-SBRT EKG&#xD;
           and echocardiography.&#xD;
&#xD;
      Patients for this study will be identified in the Radiation Oncology department as being&#xD;
      planned to receive SBRT for their lung cancer. All eligibility will be reviewed. Once a&#xD;
      patient is deemed eligible and reviewed and signed the informed consent, he/she will be asked&#xD;
      to complete the smoking questionnaire available on the state of Michigan (MI) Quitline. If a&#xD;
      patient is deemed eligible and decline to enroll, they will be asked to voluntarily complete&#xD;
      the American Heart Association (AHA) Smoking Quiz as an eligible patient exit form. Following&#xD;
      their completion of this quiz, they will be asked again if they are certain of their desire&#xD;
      to decline the study. All enrolled patients will also complete the AHA smoking quiz.&#xD;
&#xD;
      Before Treatment:&#xD;
&#xD;
      All eligibility will be confirmed and pre-treatment standard staging activities (history and&#xD;
      physical, zubrod, weight, thoracic surgeon evaluation, chest CT with contrast,&#xD;
      18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) positron emission tomography/computed&#xD;
      tomography (PET/CT), Pulmonary Function Test, bloodwork and pregnancy safety evaluation) will&#xD;
      have occurred.&#xD;
&#xD;
      A baseline pulmonologist referral will be made within 4 weeks before/after SBRT.&#xD;
&#xD;
      A baseline cardiologist referral will be made within 4 weeks before/after SBRT.&#xD;
&#xD;
      Baseline EKG and echocardiogram (ECHO) will be done prior to the 1st fraction of SBRT.&#xD;
&#xD;
      Pulmonary rehab baseline assessment including a 6 Minute Walk Test, oxygen consumption (VO2&#xD;
      max) will occur prior to treatment.&#xD;
&#xD;
      Charlson Comorbidity Index Evaluation will occur prior to treatment.&#xD;
&#xD;
      Quality of life, Depression, Anxiety, and Craving Assessment questionnaires will be&#xD;
      completed.&#xD;
&#xD;
      Subject will also have a urine or saliva Nicotine evaluation and enrollment in the Michigan&#xD;
      Tobacco Quitline program which requires a cell phone or tablet owned by the patient. This is&#xD;
      a free service within Michigan, available to any smokers, not specific for the study.&#xD;
&#xD;
      SBRT will take place as prescribed by the treating radiation oncologist within the standard&#xD;
      parameters. On-Treatment Visits (OTV) will occur weekly during the SBRT and include a history&#xD;
      and physical, zubrod (performance score), weight, hospitalization and smoking assessment, and&#xD;
      urine or saliva Nicotine evaluation . As part of the study, nicotine replacement is required&#xD;
      to be ordered as is daily visits/calls with a smoking cessation specialist.&#xD;
&#xD;
      After completion of radiotherapy, the subject will have weekly visits/calls with the smoking&#xD;
      cessation specialist for 6 weeks.&#xD;
&#xD;
      Post-Treatment visits:&#xD;
&#xD;
      At 6 weeks post SBRT-the patient will come back to the radiation oncology clinic for a&#xD;
      history and physical, zubrod, and weight. The patient also have pulmonary function testing&#xD;
      (PFT), adverse event reporting, 6 minute walk test and pulmonary rehab per plan developed&#xD;
      pre-treatment, hospitalization and smoking assessment #1 Research 4DCT, not diagnostic, will&#xD;
      be obtained at this visit and done in the radiation oncology department.&#xD;
&#xD;
      The following testing will happen, as stated at 3, 6, 9, 12, 18, 24, and then annually per&#xD;
      standard. Procedures specific to this study will be completed at 24 months. Any annual&#xD;
      testing is standard and that data will be used at the time of analysis so it is captured in&#xD;
      the patient consent and table of events.&#xD;
&#xD;
        -  History and physical exam (3, 6, 9, 12 months)&#xD;
&#xD;
        -  Performance status and weight (6, 9, 12, 18, 24, + annual)&#xD;
&#xD;
        -  Cardiologist evaluation with EKG/ECHO (6 months)&#xD;
&#xD;
        -  CT chest with contrast (3, 6, 9, 12, 18, 24, 30, 36, 42, 48 months, then annual)&#xD;
&#xD;
        -  FDG PET (3 months)&#xD;
&#xD;
        -  PFT (3, 6, 12, 18, 24 months, then annual)&#xD;
&#xD;
        -  Bloodwork- Complete blood count (CBC)/Chemistries (3 months)&#xD;
&#xD;
        -  Tumor evaluation (3, 6, 9, 12, 18, 24, then annual)&#xD;
&#xD;
        -  Adverse event (side effects) evaluation (3, 6, 9, 12, 18, 24, and annual)&#xD;
&#xD;
        -  2nd primary lung cancer documentation (not patient test-study specific notation)-(12, 24&#xD;
           months then annual)&#xD;
&#xD;
        -  6-minute walk test, V02 Max (3, 6, 12, 24, + annual)&#xD;
&#xD;
        -  QOL Assessment (3, 6, 9, 12, 18, 24, + annual)&#xD;
&#xD;
        -  Hospitalization and Smoking Assessment (3, 6, 9, 12, 18, then every 6 months to 36&#xD;
           months then annual)&#xD;
&#xD;
        -  Urine/Saliva Nicotine evaluation (6, 12, 24 months, then annual if needed)&#xD;
&#xD;
        -  Depression, Anxiety, and Craving Assessments (6, 12 months) â€¢# 2 Research 4DCT (6&#xD;
           months)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment. 1 pt. enrolled &amp; withdrew at 6 wk follow-up. No further enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, non-randomized, intervention, outcome</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of implementation of Comprehensive Care program</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>% of enrolled patients who complete study visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>an average of 10 years</time_frame>
    <description>Time from diagnosis to recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Smoking Cessation</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>% of participants who quit smoking</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Smoking</condition>
  <condition>Copd</condition>
  <arm_group>
    <arm_group_label>Comprehensive Care Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmonary rehab and smoking cessation program/intervention/assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Comprehensive Care Program</intervention_name>
    <description>Pulmonary rehabilitation and smoking cessation</description>
    <arm_group_label>Comprehensive Care Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven diagnosis of non-small cell lung cancer (NSCLC), including the&#xD;
             following types: squamous cell carcinoma, adenocarcinoma, large cell carcinoma, large&#xD;
             cell neuroendocrine carcinoma, NSCLC not otherwise specified (NOS) *Patients with&#xD;
             large cell neuroendocrine tumors must have staging MRI of the brain (or CT with IV&#xD;
             contrast if MRI contraindicated) due to the high rate of central nervous system (CNS)&#xD;
             metastasis&#xD;
&#xD;
          -  American Joint Committee on Cancer (AJCC) Lung 7th Edition clinical Stage T1-T2 N0 M0&#xD;
             with tumor less than or equal to 5 cm size&#xD;
&#xD;
          -  Patient will undergo lung SBRT with curative intent&#xD;
&#xD;
          -  Zubrod 0 - 2&#xD;
&#xD;
          -  Patient evaluated by a Thoracic surgeon and deemed medically inoperable or borderline&#xD;
             operable (candidate for only limited lung resection, either wedge resection or&#xD;
             segmentectomy) within 8 weeks. For borderline operable patients, patient has seen both&#xD;
             thoracic surgery and radiation oncology and has declined surgical intervention&#xD;
&#xD;
          -  Baseline pulmonary function tests confirm that patient would medically qualify for&#xD;
             Pulmonary Rehabilitation based on current guidelines. This means patient either has&#xD;
             COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) II-IV or meets the&#xD;
             non-COPD qualifying definition below (FVC, forced expiratory volume at one second&#xD;
             (FEV1), or diffusing capacity of lung for carbon monoxide (DLCO) &lt; 65%) AND/OR patient&#xD;
             is a current smoker (a non-COPD patient that is a smoker still has a modifiable risk&#xD;
             factor; this will be a rare condition).&#xD;
&#xD;
          -  Patient is at least 18 years of age&#xD;
&#xD;
          -  Patient is a non-pregnant female and/or a female or male practicing adequate means of&#xD;
             birth control&#xD;
&#xD;
          -  Patient has either peripheral or central lung tumor location that is radiographically&#xD;
             identifiable, with central locations as defined by either Radiation Therapy Oncology&#xD;
             Group (RTOG) 0236 or RTOG 0813 criteria and will be likely to meet dose volume&#xD;
             constraints for central mediastinal structures using one of the allowable dose&#xD;
             fractionation schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has had a synchronous primary malignancy, including lung cancer within 2&#xD;
             years, excluding non-invasive cancers or early stage skin cancers&#xD;
&#xD;
          -  Patient has had prior lung or thoracic radiotherapy, including prior lung SBRT&#xD;
&#xD;
          -  Patient is planned to receive adjuvant systemic therapy for the management of this&#xD;
             lung malignancy&#xD;
&#xD;
          -  Does not own a functional mobile/cellular communication device (cellular phone, iPhone&#xD;
             or iPad), or is not willing to incur any potential plan-specific additional charges&#xD;
&#xD;
          -  Patients who cannot perform the prescribed rehabilitation and assessments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inga Grills, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Health System</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2017</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Inga Grills</investigator_full_name>
    <investigator_title>Professor, Residency Program Director, Chief Thoracic Section</investigator_title>
  </responsible_party>
  <keyword>Comprehensive Care Program</keyword>
  <keyword>Stereotactic Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

